ASEAN and China Biosimilars Market

ASEAN and China Biosimilars Market Overview:

The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biologics experiences rapid growth in the pharmaceutical industry that fuels the development of new treatments for life-threatening and rare illnesses. However, expiry of patents of the biologics that incorporate recombinant technology has been on the rise in recent years. Thus, research-based and generic pharmaceutical companies are pursuing the opportunity to develop "generic" substitutes for original biologics that are known as biosimilars.

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

The key driving factors of the ASEAN and China biosimilars market include rise in the number of blockbuster drugs whose patents would be expiring along with high prevalence of chronic diseases among the ageing population across the ASEAN countries and China. In addition, lower cost of biosimilars drugs than original biologics has fueled the market growth. However, high initial investment in R&D is anticipated to hamper the growth of the market. Moreover, increased focus of the international key players to invest in untapped economies of the ASEAN region and China offers lucrative opportunities for expansion of the biosimilars market.

Molecule Type segment review

ASEAN and China biosimilars market comprises seven molecule types, namely, human growth hormone, erythropoietin, monoclonal antibody, insulin, interferon, granulocyte-colony stimulating factor, and peptide. The monoclonal antibody segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the diverse diagnostic applications of the monoclonal antibodies (mAbs) technology in the healthcare industry. In addition, mAbs are increasingly applied in the development of novel treatment options for cancer, infectious, cardiovascular, and inflammatory diseases. The human growth hormone segment is anticipated to grow at a rapid pace from 2018 to 2025 in the ASEAN and China biosimilars market. Increase in the development of new treatment plans that involve shift from originator to biosimilar human growth hormone across the ASEAN countries and China has contributed to the robust growth of the segment.

Application segment review

ASEAN and China biosimilars market constitutes five applications, namely, blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. The chronic and autoimmune diseases segment is further categorized into rheumatoid arthritis (RA), diabetes, glaucoma, and others. The oncology diseases segment generated the highest revenue in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to rise in healthcare expenditures owing to expensive drugs used in the treatment of cancer. This has propelled the pharmaceutical manufacturers to invest in the production of cheaper alternatives, i.e. biosimilars. However, the chronic and autoimmune diseases segment is anticipated to grow at the fastest pace during 2018-2025 in the ASEAN and China biosimilars market.

Significant increase in the preference for biosimilars such as human growth hormone and monoclonal antibodies, over branded biologics across the ASEAN countries and China has contributed to the growth of the segment. Increase in the prevalence of glaucoma and diabetes across ASEAN countries and China significantly contributed to the highest CAGR of this segment.

The major companies profiled in the report include 3SBIO Inc., Qilu Pharmaceutical, Novartis International AG (Sandoz International GmBH), Pfizer Inc. (Hospira), STADA Arzneimittel, Beijing SL Pharmaceutical Co., Ltd., Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.), Amgen Inc., AstraZeneca Plc, and Teva Pharmaceutical Industries Ltd.

Key Benefits ASEAN and China Biosimilars Market:

• The study provides an in-depth analysis along with the current trends and future estimations of the ASEAN and China biosimilars market to elucidate the imminent investment pockets.

• A comprehensive analysis of the factors that drive and restrict the market growth is provided.

• The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

• An extensive analysis of the key segments of the industry is provided to understand the molecule type and applications of biosimilars across ASEAN countries and China.

• The key players and their strategies are analyzed to understand the competitive outlook of the market.

 ASEAN and China Biosimilars Market Report Highlights